← Leaderboards
Sarah Jane Nyante
Univ Of North Carolina Chapel Hill
$3,341,530
Attributed
$3,341,530
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $777K · FY2019–23$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,341,530 · 3
By mechanism
R01$2,790,562 · 1
R21$395,468 · 1
R03$155,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Andrew Olshan$26,924,096
- Louise Henderson$9,735,205
- Henry Shelton Earp$37,241,767
- Matthew Ryen Lockett$4,035,706
- Hazel B Nichols$8,114,713
Others in their field
Other Emerging Leaders on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$29,616,650
- Abraham Aizer Brody · New York University School Of Medicine$16,015,961
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Michael P Harms · Washington University$13,645,932
- Jorge Eduardo Chavarro · Harvard School Of Public Health$12,830,103
Research focus
WomanCancer BurdenUniversitiesMalignant NeoplasmsNewly DiagnosedCancer PrognosisCharacteristicsNorth CarolinaBreast Cancer PatientMissionRadiology SpecialtyPublic HealthMalignant Breast NeoplasmAreaResponseReportingScreeningPatternStandard CareMammographyBiopsyBreast Cancer DetectionBreast Cancer DiagnosisEvidence Base
Grant awards (9)
Understanding the biological basis for the association between parenchymal texture features and breast cancer risk$485,530
R01 · FY2023 · CA · contact PI
Breast cancer neoadjuvant endocrine therapy during the Covid-19 pandemic: Opportunity for a new treatment paradigm?$213,727
R21 · FY2023 · CA · contact PI
Impact of the COVID-19 pandemic on newly-diagnosed breast cancer$77,750
R03 · FY2023 · CA · contact PI
Understanding the biological basis for the association between parenchymal texture features and breast cancer risk$503,066
R01 · FY2022 · CA · contact PI
Breast cancer neoadjuvant endocrine therapy during the Covid-19 pandemic: Opportunity for a new treatment paradigm?$181,741
R21 · FY2022 · CA · contact PI
Impact of the COVID-19 pandemic on newly-diagnosed breast cancer$77,750
R03 · FY2022 · CA · contact PI
Understanding the biological basis for the association between parenchymal texture features and breast cancer risk$604,724
R01 · FY2021 · CA · contact PI
Understanding the biological basis for the association between parenchymal texture features and breast cancer risk$585,676
R01 · FY2020 · CA · contact PI
Understanding the biological basis for the association between parenchymal texture features and breast cancer risk$611,566
R01 · FY2019 · CA · contact PI